ATLANTA -- For people with stable coronary artery disease and refractory angina, a coronary sinus reducer (CSR) implant showed a symptom alleviation benefit in the small placebo-controlled ...

Please provide your email address to receive an email when new articles are posted on . A coronary sinus reducer reduced the frequency of angina events for patients with significant CAD. However, the ...

ATLANTA, GA—An implantable coronary sinus reducer (CSR) in patients with refractory angina significantly reduces symptoms over 6 months of follow-up compared with a placebo procedure, a new study ...

ATLANTA, GA — Despite failing to increase perfusion as hypothesized, a coronary sinus reducer (CSR) in a sham-controlled randomized trial meaningfully reduced angina and improved quality of life in ...

Pressure-controlled intermittent coronary sinus occlusion (PiCSO) therapy added to primary PCI does not seem to reduce myocardial infarct size in patients with anterior ST-segment elevation myocardial ...

People with chronic chest pain who received a coronary sinus reducer (CSR)—a stent thought to increase the amount of oxygen-rich blood flowing to the heart muscle—experienced significant reductions in ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling ...

Cardiac physiologic pacing, also known as cardiac resynchronization therapy, is indicated in patients with heart failure, reduced left ventricular ejection fraction (LVEF) of 50% or less, and either a ...